

Free PDF Reliable CCRP Exam Practice & Efficient CCRP Latest Examprep: Certified Clinical Research Professional (CCRP)

CCRP SOCRA Exam - Practice Exam 1 with Complete Solutions

NB: Answers to questions appear at the bottom of the choices and are highlighted in yellow

The responsibility for ensuring that the investigator understands a clinical trial lies with which individual/or organization?

- A) FDA
- B) IRB
- C) Sponsor
- D) Coordinator

C) Sponsor

What is the minimum number of IRB Members?

- A) 3
- B) 5
- C) 6
- D) 10

B) 5

A significant risk device is defined as an investigational device that is:

- A) Intended as an implant and presents a potential for serious risk to the health, safety, or welfare

Our company has taken a lot of measures to ensure the quality of our CCRP preparation materials. It is really difficult for us to hire a professional team, regularly investigate market conditions, and constantly update our CCRP exam questions. But we persisted for so many years. And our quality of our CCRP study braindumps are praised by all of our worthy customers. And you can always get the most updated and latest CCRP training guide if you buy them.

SOCRA CCRP Exam Syllabus Topics:

Topic	Details

Topic 1	<ul style="list-style-type: none"> • Research Study Start-Up: This section of the exam measures the skills of Clinical Research Coordinators and covers the initial planning and setup of a clinical trial. It involves coordinating the development of the study protocol, ensuring it considers ethical guidelines and regulatory pathways like IND or IDE. It also includes creating essential study documents like informed consent forms and case report forms. The domain covers obtaining necessary approvals from stakeholders like the IRB and sponsor, selecting study sites, training staff, and ensuring the study's compliance with various laws. Additionally, it involves obtaining the research product and preparing all necessary tools and documentation for the study's commencement. Research Study Implementation: This section of the exam measures the skills of Clinical Research Associates and covers the active management and execution of the clinical trial. It focuses on following the study protocol and standard operating procedures, managing the investigational product, and ensuring ongoing regulatory compliance. The domain includes identifying, documenting, and reporting any study anomalies such as adverse events or protocol deviations. It also involves managing subject recruitment, consent, and retention, as well as maintaining all study records and essential documents. Furthermore, it covers communicating with all study stakeholders and participating in study audits to ensure quality and adherence to regulations.
Topic 2	<ul style="list-style-type: none"> • Research Study Closure: This section of the exam measures the skills of Clinical Research Coordinators and covers the activities required to properly conclude a clinical trial. It involves participating in the study closeout visit to verify documentation and account for the investigational product. The domain also includes developing and submitting final closure reports to the IRB, study sponsor, regulatory authorities, and clinicaltrials.gov. Finally, it covers the procedures for archiving study records.

>> Reliable CCRP Exam Practice <<

CCRP Latest Examprep - CCRP Practice Engine

As long as you are willing to buy our CCRP preparation exam, coupled with your careful preparation, we can guarantee that you will get the CCRP certification for sure for we have been the brand in this field and welcomed by tens of thousands of our customers. Not only save you a lot of time and energy, but also can make your mood no longer anxious on the coming CCRP Exam. So, for your future development, please don't hesitate to use our CCRP actual exam.

SOCRA Certified Clinical Research Professional (CCRP) Sample Questions (Q130-Q135):

NEW QUESTION # 130

A nonrandomized study of 30 subjects entitled "A study to evaluate the effectiveness of and to determine the common short-term side effects associated with the drug 'PainStop' for the treatment of subjects with chronic arthritis" is an example of a:

- A. Phase III
- B. Phase II
- C. Phase IV
- D. Phase I

Answer: B

Explanation:

Phase classification is based on study objectives, not just subject numbers.

* Phase I:Focuses on safety, pharmacokinetics, dose-ranging, usually in healthy volunteers or small patient groups.

* Phase II:Evaluatesthe effectiveness in patients with the conditionand monitors common short-term side effects.

* Phase III:Confirms effectiveness in larger populations, compares to standard therapy, gathers more safety data.

* Phase IV:Post-marketing studies exploring new indications, long-term safety, or special populations.

The given study aims to evaluate effectiveness and common short-term side effects in 30 arthritis patients, which clearly aligns with Phase II objectives. It is not exploratory safety (Phase I), not confirmatory comparative (Phase III), nor post-marketing (Phase IV).

Thus, the correct answer is B (Phase II).

References:

FDA Guidance: The IND Application - §312.21 (Phases of an investigation).
ICH E8(R1), General Considerations for Clinical Studies.

NEW QUESTION # 131

Which of the following statements about the FDA's authority to inspect IRB/IEC records is correct?

- A. The FDA may inspect them only if the IRB/IEC formally requests inspection
- B. The FDA does not have regulatory authority to inspect them
- C. The FDA may inspect them at reasonable times, in a reasonable manner, but may not take copies unless requested with an affidavit
- D. **The FDA may inspect them at reasonable times, in a reasonable manner, and may take copies of IRB/IEC records**

Answer: D

Explanation:

The FDA has full regulatory authority to inspect IRB/IEC records.

* 21 CFR 56.115(b): "The IRB shall permit representatives of the Food and Drug Administration to inspect and copy all records maintained... at reasonable times and in a reasonable manner." Thus, FDA may inspect and copy IRB/IEC records without requiring an affidavit or invitation. This ensures regulatory oversight and human subject protection.

Incorrect options:

- * (A) limits authority incorrectly.
- * (C) is false - FDA explicitly regulates IRBs.
- * (D) is false - FDA does not need IRB invitation.

Correct answer: B.

References:

21 CFR 56.115(b).

NEW QUESTION # 132

If a subject experiences a serious adverse event related to the study drug and only minimal information is available, the investigator must submit the information to the:

- A. IRB/IEC immediately, then sponsor when full details are available
- B. Sponsor and IRB/IEC within seven days
- C. **Sponsor and IRB/IEC immediately, then update later**
- D. Sponsor and IRB/IEC within five days

Answer: C

Explanation:

* ICH E6(R2) 4.11.1: Investigators must "immediately report all serious adverse events to the sponsor except for those the protocol identifies as not requiring immediate reporting."

* IRB must also be informed promptly per 21 CFR 312.64(b).

* Follow-up information is submitted later as available.

References: ICH E6(R2), §4.11.1; 21 CFR 312.64(b).

NEW QUESTION # 133

During an internal compliance review, the site study team identified that a protocol-required blood sample collection was not obtained for a majority of the subjects enrolled. In accordance with the ICH GCP Guideline, the clinical investigator should:

- A. Suspend all trial-related activities until the events of the deviation have been mitigated
- B. **Document and explain the deviation from the protocol**
- C. Assign another investigator to perform sample collections until an internal investigation is completed
- D. Immediately report the observation to the regulatory authority

Answer: B

Explanation:

ICH directs investigators to document and explain any deviation, with prompt reporting to IRB/IEC only when deviations are implemented to eliminate immediate hazards or as required. Exact extracts:

- * ICH E6(R2) 4.5.3: "The investigator should document and explain any deviation from the approved protocol."
- * ICH E6(R2) 3.3.7 & 4.5.2 (paraphrased): deviations to eliminate immediate hazards must be reported as soon as possible. Here, absent immediate hazard, the required action is documentation and explanation (B).

References:

- ICH E6(R2) Good Clinical Practice, §4.5.3 (Compliance with protocol; deviations).
- ICH E6(R2) §3.3.7; §4.5.2 (Reporting deviations implemented to eliminate immediate hazards).

NEW QUESTION # 134

Upon completion of a study, the investigator should do which of the following?

- A. Provide the IRB/IEC a final report, but only if the study has a positive outcome
- B. **As soon as possible, provide the IRB/IEC with a final report that summarizes the trial's outcome**
- C. Compile site data, publish the study results, and submit the publication to the IRB/IEC as the final report
- D. Ensure that all payments from sponsor have been received

Answer: B

Explanation:

Investigators must formally close out a trial with the IRB/IEC.

- * ICH E6(R2) 4.13.2: "Upon completion of the trial, the investigator/institution should provide the IRB/IEC with a summary of the trial's outcome."

* 21 CFR 312.66: Reinforces investigator's duty to keep IRB informed throughout study lifecycle.

This applies regardless of whether outcomes were positive, negative, or inconclusive. IRBs are not concerned with sponsor payments (B) or publications (D).

Thus, the correct answer is A (Provide final report to IRB/IEC).

References:

- ICH E6(R2), §4.13.2 (Final reporting requirement).

NEW QUESTION # 135

.....

Our company attaches great importance on improving the CCRP study prep. In addition, we clearly know that constant improvement is of great significance to the survival of a company. The fierce competition in the market among the same industry has long existed. As for our CCRP exam braindump, our company masters the core technology, owns the independent intellectual property rights and strong market competitiveness. What is more, we have never satisfied our current accomplishments. Now, our company is specialized in design, development, manufacturing, marketing and retail of the CCRP Test Question, aimed to provide high quality product, solutions based on customer's needs and perfect service of the CCRP exam braindump. At the same time, we have formed a group of passionate researchers and experts, which is our great motivation of improvement. Every once in a while we will release the new version study materials. You will enjoy our newest version of the CCRP study prep after you have purchased them. Our ability of improvement is stronger than others. New trial might change your life greatly.

CCRP Latest Examprep: <https://www.dumpstests.com/CCRP-latest-test-dumps.html>

- CCRP Minimum Pass Score CCRP Exam Forum New Study CCRP Questions Search for CCRP and easily obtain a free download on www.examdiscuss.com CCRP Valid Exam Experience
- Quiz 2025 SOCRA Valid Reliable CCRP Exam Practice Search on www.pdfvce.com for CCRP to obtain exam materials for free download CCRP Exam Forum
- Web-based SOCRA CCRP Practice Exam Software - Solution for Online Self-Assessment www.passtestking.com is best website to obtain CCRP for free download Free CCRP Exam
- Valid CCRP Practice Materials Reliable CCRP Guide Files Valid CCRP Practice Materials Copy URL www.pdfvce.com open and search for CCRP to download for free CCRP New Soft Simulations
- CCRP Valuable Feedback CCRP Online Lab Simulation CCRP Valuable Feedback Enter www.itcerttest.com and search for www.itcerttest.com to download for free Reliable CCRP Guide Files
- Quiz 2025 SOCRA Valid Reliable CCRP Exam Practice Search on www.pdfvce.com for CCRP to obtain exam materials for free download Free CCRP Exam
- CCRP Exam Certification CCRP Latest Exam Reliable CCRP Test Book Copy URL www.testsimulate.com open and search for CCRP to download for free CCRP Valid Exam Experience

